In focus · trending topic

solithromycin

37 stories · following the connections

Cempra Reports Third Quarter 2016 Financial Results and Provides Corporate Update

By Nasdaq OMXOct 27, 2016, 8:17 PM UTC

Cempra Reports Third Quarter 2016 Financial Results and Provides Corporate Update

By Nasdaq OMXOct 27, 2016, 8:17 PM UTC

Cempra to Report Third Quarter 2016 Financial Results

By Nasdaq OMXOct 25, 2016, 8:15 PM UTC

Cempra Presents Analysis Showing Rates of Failure for Existing CABP Antibiotics From Claims Database at Academy of Managed Care Pharmacy Meeting

By Nasdaq OMXOct 4, 2016, 8:15 PM UTC

Cempra Announces Anti-NASH Effects of Solithromycin: Interim Results From Phase 2 Study

By Nasdaq OMXSep 29, 2016, 8:15 PM UTC

Cempra to Present at Three Upcoming Investor Conferences

By Nasdaq OMXSep 1, 2016, 11:30 AM UTC

Cempra to Present Solithromycin at FDA Antimicrobial Drugs Advisory Committee Meeting on November 4, 2016

By Nasdaq OMXAug 30, 2016, 1:15 PM UTC

Cempra’s Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases

By Nasdaq OMXAug 25, 2016, 8:05 PM UTC